Give Dogs More Days of Play

Librela offers long-lasting pain relief with a once-monthly injection administered by your vet.1

Osteoarthritis (OA), or arthritis, is a painful chronic condition of the joints. Pain from OA can severely affect the health and well-being of your dog.2 Although we cannot cure OA, we can control the pain it causes.

Ask your vet about the newest osteoarthritis injection for dogs.

Are you missing the signs of your dog’s OA pain? Complete our quick checklist.
illustration of dog with checkmark
Librela product image

One Monthly Injection of Librela Can Reduce Your Dog's OA Pain

By reducing OA pain and helping to restore mobility, Librela protects the unique bond they share with you.1-4

Why Librela for Dogs?

  • By decreasing OA pain, Librela can increase your dog's activity and improve their quality of life.1, 3, 4
  • Effectively controls Canine OA pain with a monthly injection.1
  • Functions like naturally occurring antibodies that are easy on your dog's liver and kidneys.1, 5, 6
  • Available in Europe since 2021, with over 4.6 million doses distributed.7
Illustration of pack of dogs

Long-Lasting Relief From OA Pain Can Result in a Happier, More Active Dog

Relief from OA pain doesn’t just restore mobility, it renews happiness. By reducing pain, Librela can give you more precious moments in comfort with your best friend.1, 2 Talk to your vet about an OA screening and how treatment with Librela can make a big difference.

Vet-Approved Support

Librela FAQ

IMPORTANT SAFETY INFORMATION: See full Prescribing Information. For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis.

  1. Librela (bedinvetmab injection). Prescribing information. NADA 141-562. Zoetis Inc; March 2023.
  2. Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78. doi:10.1016/j. tvjl.2019.07.001.
  3. Brown DC, Boston RC, Coyne JC, Farrar JT. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res. 2007;68(6):631-637. doi:10.2460/ajvr.68.6.631.
  4. Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the Canine Brief Pain Inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278-1283. doi:10.2460/ javma.233.8.1278.
  5. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507. doi:10.2165/11531280.
  6. Olivry T, Bainbridge G. Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. Zoetis. March 2015. resources/publications/zoetiscn_mar_fnl.pdf.
  7. Data on File. November 2022.
  8. Corral, Maria J., et al. "A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis." Veterinary anaesthesia and analgesia 48.6 (2021): 943-955.